首页> 外国专利> Antibody Drug Conjugates against 5T4 Antigen expressed in tumor initiating Cells

Antibody Drug Conjugates against 5T4 Antigen expressed in tumor initiating Cells

机译:抗体药物结合抗肿瘤起始细胞中表达的5T4抗原

摘要

It describes the combination of anti-5t4-drug antibodies and the method of preparing and using them. In some ways, the drug is a headset like MMAF, MMAE. The current antibody drug conjugates bind to tumor cells expressing 5T4 antigen and provide sufficient cytotoxic drugs for cells by providing cancer treatment. 1. Claim 1: a group of antibodies in the formula: ab - (lu-d) 8346; or a salt acceptable in medicine; a) AB is an anti-5T4 antibody or part of one of the antigens,It includes a variable area in the heavy chain, as shown in SEQ ID No.5, including: (1) a VH CDR1 area, (2) a VH CDR2 area, as shown in SEQ ID No.6, and (3) a VH CDR3 area, as shown in SEQ ID No.7; (b) Lu is a paired unit selected from this group, consisting of maleimetropiro and maleimetropilo Val CIT; (c) P is an integer of about 1 to 8; (d) d is a pharmacological unit selected from this group, consisting of MMAE, MMAD and MMAF.
机译:它描述了抗5t4药物抗体的组合及其制备和使用方法。在某些方面,这种药物是像MMAF,MMAE这样的头戴式耳机。当前的抗体药物缀合物结合表达5T4抗原的肿瘤细胞并通过提供癌症治疗为细胞提供足够的细胞毒性药物。 1.权利要求1:一组下式的抗体:ab-(lu-d)8346;和或医学上可接受的盐; a)AB是抗5T4抗体或一种抗原的一部分,它在重链中包含一个可变区,如SEQ ID No.5所示,包括:(1)VH CDR1区,(2)a VH CDR2区域,如SEQ ID No.6所示;(3)VH CDR3区域,如SEQ ID No.7所示; (b)Lu是从这一组中选出的配对单位,由马来烯丙四醇和马来烯丙四醇Val CIT组成; (c)P是大约1到8的整数; (d)d是选自该组的药理学单元,由MMAE,MMAD和MMAF组成。

著录项

  • 公开/公告号AR085747A1

    专利类型

  • 公开/公告日2013-10-23

    原文格式PDF

  • 申请/专利权人 WYETH LLC;

    申请/专利号AR2012P101072

  • 发明设计人

    申请日2012-03-29

  • 分类号C07K16/28;A61K39/395;A61K47/48;A61P35;C12P21;

  • 国家 AR

  • 入库时间 2022-08-21 16:42:29

相似文献

  • 专利
  • 外文文献
  • 中文文献
获取专利

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号